However, taking into account that FLT3-directed first-line therapy during induction was not standard therapy when investigating the effect of sorafenib after alloHSCT, the optimal treatment/maintenance therapy after alloHSCT for FLT3pos AML is not set. The gene discussed is FLT3; the disease is acute myeloid leukemia.